证券代码：688265 证券简称：南模生物 公告编号：2025-045 上海南方模式生物科技股份有限公司 关于持股 5%以上股东及其一致行动人权益变动触及 ? 本次权益变动为上海南方模式生物科技股份有限公司（以下简称"公司" 或"上市公司"）股东增持股份所致，不触及要约收购，不会导致上市公司控股股 东、实际控制人发生变化。 信息披露义务人上海浦东新兴产业投资有限公司保证向本公司提供 的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信 息一致。 ? 截至本公告披露日，苏州海望合纵一号股权投资合伙企业（有限合伙） （以下简称"海望合纵"）在本次权益变动前通过协议转让方式受让的 8,679,727 股公司股份尚未在中国证券登记结算有限责任公司上海分公司办理完成股份转 让过户登记手续，交易能否最终完成尚存在不确定性，敬请广大投资者注意投资 风险。 一、 信息披露义务人及其一致行动人的基本信息 □控股股东/实际控制人及其一致行动人 投资者及其一致行动人的身份 重要内容提示： 权益变动方向 比例增加 比例减少□ 权益变动前合计比例 15.00% 权益变 ...

Core Viewpoint - Nanmo Biotechnology (688265.SH) received a notification from its shareholder, Shanghai Pudong New Industry Investment Co., Ltd., regarding a change in equity that triggered a 1% threshold increase in shareholding [1] Group 1 - Shanghai Pudong New Industry increased its holdings in Nanmo Biotechnology by acquiring a total of 1,633,976 unrestricted circulating shares through centralized bidding from July 31, 2025, to August 4, 2025 [1] - The shareholding ratio of Shanghai Pudong New Industry and its concerted action party, Haiwang Hezhong, rose from 15.00% to 17.10% following this transaction [1]

证券代码：688265 证券简称：南模生物 公告编号：2025-045 上海南方模式生物科技股份有限公司 关于持股 5%以上股东及其一致行动人权益变动触及 1%整数倍的提示性公告 信息披露义务人上海浦东新兴产业投资有限公司保证向本公司提供 的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信 息一致。 本次权益变动为上海南方模式生物科技股份有限公司（以下简称"公司" 或"上市公司"）股东增持股份所致，不触及要约收购，不会导致上市公司控股股 东、实际控制人发生变化。 截至本公告披露日，苏州海望合纵一号股权投资合伙企业（有限合伙） （以下简称"海望合纵"）在本次权益变动前通过协议转让方式受让的 8,679,727 股公司股份尚未在中国证券登记结算有限责任公司上海分公司办理完成股份转 让过户登记手续，交易能否最终完成尚存在不确定性，敬请广大投资者注意投资 风险。 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | 投资者及其一致行动人的身份 | □控股股东/实际控制人及其一致行动人 | | --- | --- | | | ☑其他 5%以 ...

Group 1 - The closing price of Nanmo Biology (688265) on August 4 was 43.73 yuan, reaching the daily limit with a trading volume of 1.66 billion yuan and a turnover rate of 5.24% [1] - The stock was listed on the trading board due to a price increase of 15% at the close of the day [1] - The top five trading departments accounted for a total transaction amount of 1.08 billion yuan, with a net buying amount of 49.15 million yuan [1] Group 2 - The largest buying department was Industrial Securities Co., Ltd. Shanghai Branch, with a buying amount of 56.97 million yuan [1] - The selling department included one institutional special seat, which sold 7.65 million yuan, contributing to a total selling amount of 21.92 million yuan [1] - The net inflow of main funds for the stock was 28.20 million yuan throughout the day [1]

证券之星消息，8月4日医疗服务板块较上一交易日下跌0.26%，昭衍新药领跌。当日上证指数报收于 3583.31，上涨0.66%。深证成指报收于11041.56，上涨0.46%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | --- | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 43.73 | 20.01% | | 4.08万 | 1.66亿 | | 688621 | 阳光诺和 | 66.54 | 14.84% | | 12.60万 | 8.15亿 | | 301201 | 诚达药业 | 28.10 | 4.04% | | 10.58万 | 2.93亿 | | 688222 | 成都先导 | 24.74 | 3.82% | | 33.55万 | 7.91亿 | | 002172 | 澳洋健康 | 4.25 | 3.41% | | 70.07万 | 2.93亿 | | 688046 | 药康生物 | 16.41 | 3.01% | | 4.55万 | 7293.23万 | | ...

Core Viewpoint - TianTan Biological experienced a sharp increase in stock price, reaching the daily limit, while other companies in the sector such as Keta Bio, Nanmo Bio, and Sairun Bio saw their stock prices rise by over 10% [1] Company Performance - TianTan Biological's stock price hit the daily limit, indicating strong market interest and confidence in the company [1] - Keta Bio, Nanmo Bio, and Sairun Bio also showed significant gains, with stock prices increasing by more than 10%, reflecting positive sentiment in the biotechnology sector [1] - Watson Bio and Anxu Bio, among others, followed suit with notable increases in their stock prices, suggesting a broader rally in the biotechnology industry [1]

科创板个股中，截至发稿上涨的共有439只，涨幅在10%以上的共有14只，除南模生物之外，涨停的还 有兴图新科、科思科技等，下跌的有144只，跌幅较大的有科兴制药、奥浦迈、容百科技，分别下跌 9.24%、5.90%、5.70%。 资金面上，南模生物上一交易日主力资金净流出269.58万元，近5日净流出610.19万元。 8月4日盘中科创板股南模生物涨停，截至14:09，股价报43.73元，成交1.12亿元，换手率3.63%，振幅 21.19%。 融资融券数据显示，该股最新（8月1日）两融余额为7593.36万元，其中，融资余额为7593.36万元，较 上一个交易日减少59.85万元，降幅为0.78%；近10日两融余额合计增加1719.55万元，增幅为29.27%， 其间融资余额增长29.27%。（数据宝） （文章来源：证券时报网） ...

Group 1 - The core viewpoint of the article highlights the significant progress made in HIV vaccine research in China, with the completion of the first Phase I clinical trial of a recombinant Tian Tan smallpox vaccine-based HIV vaccine [1] - The innovative approach utilizes the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, as a vector for the vaccine, demonstrating safety and the ability to elicit an effective immune response [1] - Following this announcement, the A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting the daily limit of 10% [1]

Group 1 - The A-share market saw a surge in biopharmaceutical stocks, with notable increases including Nanmo Bio and Sairun Bio rising over 14%, and Tiantan Bio hitting a 10% limit up [1] - The China CDC and other teams completed the first Phase I clinical trial of a replicative Tian Tan smallpox vaccine-based HIV vaccine, marking a significant advancement in HIV vaccine research in China [1] - The innovative approach utilized the "Tian Tan strain" smallpox virus, previously used to eradicate smallpox, to verify the safety and effective immune response of the vaccine [1]

Core Viewpoint - The announcement details a change in shareholding for Shanghai Nanmo Biological Technology Co., Ltd., indicating an increase in shares held by Shanghai Pudong New Industry Investment Co., Ltd. and its concerted action party, without triggering a mandatory takeover or changing the controlling shareholder [1][2]. Summary by Sections Shareholding Changes - Prior to the change, Shanghai Pudong New Industry held 2,160,000 shares, representing 2.77% of the total share capital, while its concerted action party, Suzhou Haiwang Hezong No.1 Equity Investment Partnership, held 8,679,727 shares, or 11.13%. Together, they held 10,839,727 shares, accounting for 13.90% of the total [1][3]. - On July 16, 2025, Pudong New Industry increased its holdings by 854,800 shares, bringing its total to 3,014,800 shares, or 3.87%. The combined holdings of Pudong New Industry and Haiwang Hezong now total 11,694,527 shares, or 15.00%, reaching a 5% integer multiple [2][3]. Funding Source - The funds used for the share increase by Pudong New Industry were sourced entirely from its own capital, confirming the legality of the funding [4]. Compliance and Regulatory Notes - The share transfer of 8,679,727 shares by Haiwang Hezong is pending compliance confirmation from the Shanghai Stock Exchange and must complete the transfer registration with the China Securities Depository and Clearing Corporation [2][3].